超声造影
指南
对比度(视觉)
超声波
医学物理学
医学
放射科
食品药品监督管理局
协议(科学)
计算机科学
病理
风险分析(工程)
替代医学
人工智能
作者
Christoph F. Dietrich,Christian Nolsøe,R. Graham Barr,Annalisa Berzigotti,Peter N. Burns,Vito Cantisani,Maria Cristina Chammas,Nitin Chaubal,Byung Ihn Choi,Dirk‐André Clevert,Xin‐Wu Cui,Yi Dong,Mirko D’Onofrio,J. Brian Fowlkes,Odd Helge Gilja,Pintong Huang,A Ignee,Christian Jenssen,Yuko Kono,Masatoshi Kudo
标识
DOI:10.1016/j.ultrasmedbio.2020.04.030
摘要
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI